sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?

Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with organ failure due to COVID-19 represents a major healthcare burden. While endothelial inflammation has been reported in these patients, the pathophysiological mechanisms remain incompletely elucidated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronavirus Infections Coronaviridae Infections Infections Nidovirales Infections RNA Virus Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Reims

Reims, 51092, France

About this study

Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures. (Limit : 32 000 characters)

The soluble fms-like tyrosine kinase 1 (SFlt1) is the soluble form of VEGF-A receptor 1 (VEGFR1). By linking VEGF-A with a high affinity, sFlt1 blocks the VEGF-A / VEFR1 axis and impairs endothelial homeostasis. Its production increases during inflammation. We hypothesize that sFlt1 is upregulated and correlates with endothelial dysfunction and outcomes in critically-ill patients with COVID-19.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient with documented COVID-19 (positive PCR)
Hospitalized in University Hospital of Reims
Patient or family who have previously consented

Exclusion criteria

Patient <18 yo
Patient not insured under the French social security

Treatment and study plan

measurement of circulating sFlt1 concentration

Other

blood circulating sFlt1 concentration will be determined

Primary outcomes

Association between concentration of circulating sFlt1 and use of vasopressor

Time frame: 14 days

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Acronym: COVIDsFlt1

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: May 19, 2020
Registry last updated: Apr 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed